Vitamin E as an antioxidant agent in CAPD patients.
Oxidative stress, increased lipid peroxidation and decreased activity of antioxidant systems may contribute to the accelerated development of atherosclerosis in chronic renal failure patients during renal replacement therapy. The aim of the study was to investigate the influence of vitamin E (400 mg/day) on some antioxidant defense parameters in CAPD patients. In fourteen CAPD patients, erythrocyte antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPX) and catalase (CAT), the concentration of plasma malondialdehyde (MDA), vitamin A, vitamin C and vitamin E were investigated. The study was divided into two periods. Each period lasted six weeks. In the first period patients received orally vitamin E 400 mg/day, in the second period they did not receive vitamin E or other antioxidant drugs. Each parameter was determined at the beginning of the study and at the end of each period. Six CAPD patients were treated by erythropoietin (EPO) and received orally pyridoxine 20 mg/day and the others without EPO treatment received pyridoxine 5 mg/day. Six-week treatment by vitamin E (400 mg/day) led to the significant increase of serum vitamin E (from 33.6+/-9.0 to 49.3+/-15.5 micromol/L) and to the significant decrease of MDA (from 2.62+/-0.5 to 2.36+/-0.4 micromol/L). The mean values of erythrocyte enzymes were in or under the lower margin of normal range and were not influenced by vitamin E in CAPD patients. The results of our study showed that orally administered vitamin E is a very important antioxidant agent for CAPD patients.
Mydlík
M
M
Nephrological Clinic, University Hospital, Kosice, Slovak Republic.
Derzsiová
K
K
Rácz
O
O
Sipulová
A
A
Boldizsár
J
J
Lovásová
E
E
Hríbiková
M
M
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D000975:Antioxidants / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control*; D004912:Erythrocytes / Q000201:enzymology; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D015227:Lipid Peroxidation; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage* / Q000493:pharmacokinetics
D000975:Antioxidants; D004921:Erythropoietin; D014810:Vitamin E